RNAZ TransCode Therapeutics, Inc.: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

TransCode Therapeutics (RNAZ) utilizes the innovative TTX system for the targeted destruction of metastases. The 12-month annual growth in earnings per share illustrates the financial dynamics, where the current level is 86.80. However, a liquidity deficit and shareholder dilution, combined with the risks of disrupted logistics chains from Asia, are exerting significant pressure on the company's capitalization.

The operational dynamics of TransCode Therapeutics (RNAZ) are reflected in the rolling year-over-year (YoY) change in earnings per share. This metric captures the annual growth of net income attributable to a single common share, with calculations based on a comparison of the current TTM value against the same period last year. Within the biotechnology sector, this trend is secondary to the clinical success of RNA therapy. Investors utilize this chart to monitor financial stability during capital raising periods.